Class information for:
Level 1: ANAPLASTIC THYROID CANCER//ANAPLASTIC THYROID CARCINOMA//LENVATINIB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
12687 826 36.9 80%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
35 32606 THYROID CANCER//THYROID//THYROGLOBULIN

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANAPLASTIC THYROID CANCER Author keyword 37 50% 7% 54
2 ANAPLASTIC THYROID CARCINOMA Author keyword 37 44% 8% 63
3 LENVATINIB Author keyword 17 70% 2% 14
4 VANDETANIB Author keyword 12 27% 5% 38
5 UNDIFFERENTIATED THYROID CANCER Author keyword 11 78% 1% 7
6 REFERENCE TUMEURS REFRACTAI THYROIDE Address 9 83% 1% 5
7 ANAPLASTIC CARCINOMA Author keyword 7 24% 3% 26
8 E7080 Author keyword 7 67% 1% 6
9 ENDOCRINE NEOPLASIA HORMONAL DISORDERS Address 4 11% 4% 35
10 MEDULLARY THYROID CANCER Author keyword 4 12% 3% 27

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ANAPLASTIC THYROID CANCER 37 50% 7% 54 Search ANAPLASTIC+THYROID+CANCER Search ANAPLASTIC+THYROID+CANCER
2 ANAPLASTIC THYROID CARCINOMA 37 44% 8% 63 Search ANAPLASTIC+THYROID+CARCINOMA Search ANAPLASTIC+THYROID+CARCINOMA
3 LENVATINIB 17 70% 2% 14 Search LENVATINIB Search LENVATINIB
4 VANDETANIB 12 27% 5% 38 Search VANDETANIB Search VANDETANIB
5 UNDIFFERENTIATED THYROID CANCER 11 78% 1% 7 Search UNDIFFERENTIATED+THYROID+CANCER Search UNDIFFERENTIATED+THYROID+CANCER
6 ANAPLASTIC CARCINOMA 7 24% 3% 26 Search ANAPLASTIC+CARCINOMA Search ANAPLASTIC+CARCINOMA
7 E7080 7 67% 1% 6 Search E7080 Search E7080
8 MEDULLARY THYROID CANCER 4 12% 3% 27 Search MEDULLARY+THYROID+CANCER Search MEDULLARY+THYROID+CANCER
9 THYROID CANCER TREATMENT 3 60% 0% 3 Search THYROID+CANCER+TREATMENT Search THYROID+CANCER+TREATMENT
10 ZD6474 3 22% 1% 11 Search ZD6474 Search ZD6474

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ZD6474 21 37% 6% 46
2 E7080 21 78% 2% 14
3 GIANT CELL CARCINOMA 20 58% 3% 23
4 VANDETANIB 16 41% 4% 29
5 MOTESANIB 13 69% 1% 11
6 DOXORUBICIN PLUS CISPLATIN 12 33% 4% 30
7 PROGRESSIVE MEDULLARY 8 100% 1% 5
8 CABOZANTINIB 4 39% 1% 9
9 ONCOGENIC RET 3 35% 1% 7
10 RADIOIODINE UPTAKE 2 17% 2% 13

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis 2015 3 43 65%
Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches 2006 150 88 65%
An update on clinical trials of targeted therapies in thyroid cancer 2014 10 29 76%
Sorafenib in Metastatic Thyroid Cancer: A Systematic Review 2014 9 35 66%
Advances in thyroid cancer treatment: latest evidence and clinical potential 2015 3 70 46%
Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer 2014 4 20 80%
Approach to the patient with advanced differentiated thyroid cancer 2012 37 39 51%
Anaplastic thyroid cancer 2003 114 49 69%
Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review 2011 16 23 91%
Multikinase inhibitors: a new option for the treatment of thyroid cancer 2011 59 56 39%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 REFERENCE TUMEURS REFRACTAI THYROIDE 9 83% 0.6% 5
2 ENDOCRINE NEOPLASIA HORMONAL DISORDERS 4 11% 4.2% 35
3 CONSORTIUM CANC THYROIDIEN 3 100% 0.4% 3
4 SERV MED NUCL ONCOL ENDOCRINIENNE 3 60% 0.4% 3
5 CANC MEDUNIT 455 2 67% 0.2% 2
6 NUCL MED ENDOCRINE ONCOL 2 11% 2.3% 19
7 ONCOL ENDOCRINOL UNIT 2 43% 0.4% 3
8 ENDOCRINE MALIGNANCIES DIS ORIENTED GRP 1 50% 0.2% 2
9 ISKUM 1 100% 0.2% 2
10 S MARIA UNIV HOSP 1 50% 0.2% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000221566 RET PTC//PAPILLARY THYROID CARCINOMA//HBME 1
2 0.0000141286 INSULAR CARCINOMA//COLUMNAR CELL CARCINOMA//HURTHLE CELL CARCINOMA
3 0.0000137478 MEDULLARY THYROID CARCINOMA//RET PROTO ONCOGENE//MEDULLARY THYROID CANCER
4 0.0000134369 THYROID LYMPHOMA//PRIMARY THYROID LYMPHOMA//MALIGNANT LYMPHOMA OF THE THYROID
5 0.0000123465 SODIUM IODIDE SYMPORTER//SODIUM IODIDE SYMPORTER NIS//IODIDE TRANSPORT
6 0.0000121301 DIFFERENTIATED THYROID CANCER//THYROGLOBULIN//DIFFERENTIATED THYROID CARCINOMA
7 0.0000106226 SOLID CELL NESTS//THYROID METASTASIS//ULTIMOBRANCHIAL BODY
8 0.0000085349 FAMILIAL NON MEDULLARY THYROID CANCER//FAMILIAL THYROID CARCINOMA//CANC MOL GENET GEMOCA
9 0.0000075107 SUNITINIB//METASTATIC RENAL CELL CARCINOMA//CARCINOMA RENAL CELL
10 0.0000068062 ENDOCRINE SURG S//ACHAETE SCUTE COMPLEX LIKE 1//CLIN SCI H4 750